These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8063263)

  • 1. Mathematical modeling of erythropoietin therapy in uremic anemia. Does it improve cost-effectiveness?
    Bellazzi R; Siviero C; Bellazzi R
    Haematologica; 1994; 79(2):154-64. PubMed ID: 8063263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children.
    Allen UD; Kirby MA; Goeree R
    Pediatr AIDS HIV Infect; 1997 Feb; 8(1):4-11. PubMed ID: 11361510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does anemia correction by rHuEPO improve uremic cardiopathy?
    Carletti P; Bibiano L; Boggi R; Taruscia D; Mioli V
    Kidney Int Suppl; 1993 Jun; 41():S70-1. PubMed ID: 8320949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug delivery optimization through Bayesian networks.
    Bellazzi R
    Proc Annu Symp Comput Appl Med Care; 1992; ():572-8. PubMed ID: 1482938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer.
    Henry DH
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):12-6. PubMed ID: 8153671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of iron status monitoring during erythropoietin treatment in uremic predialysis patients.
    Rutkowski B; Debska-Slizień A; Biedunkiewicz B; Bułło B
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():17-21. PubMed ID: 8192528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer].
    Bösze P; Mayer A; Thurzó L; Kiss A; Rák K; Stumpf J
    Orv Hetil; 1995 Nov; 136(47):2567-72. PubMed ID: 8532322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of the anemia of multiple myeloma: the role of recombinant human erythropoietin.
    Barlogie B
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):25-7. PubMed ID: 8153675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A therapeutical approach by administering reduced glutathione to patients with uremic anemia].
    Xia N; Qu S
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Jun; 32(2):300-2. PubMed ID: 12600115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J; Koch KM
    Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Zealand cancer patients should have access to erythropoietin treatment.
    Carter J; Clay J
    N Z Med J; 2006 May; 119(1234):U1989. PubMed ID: 16718300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PHARMAC and erythropoietin for cancer patients.
    Grocott R; Metcalfe S; Moodie P
    N Z Med J; 2006 Jun; 119(1236):U2039. PubMed ID: 16807581
    [No Abstract]   [Full Text] [Related]  

  • 15. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
    Roger SD; Baker LR; Raine AE
    Clin Nephrol; 1993 Feb; 39(2):103-10. PubMed ID: 8448912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug delivery optimization through Bayesian networks: an application to erythropoietin therapy in uremic anemia.
    Bellazzi R
    Comput Biomed Res; 1993 Jun; 26(3):274-93. PubMed ID: 8325006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin (r-HuEPO) in the treatment of anemia of nodular sclerosis type Hodgkin's disease--a preliminary report.
    Wojtukiewicz MZ; Sawicki Z; Radziwon P
    Rocz Akad Med Bialymst; 2000; 45():145-9. PubMed ID: 11712426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma].
    Spicka I; Haber J; Petruzelka L; Kolesková E; Sálková J; Straub J; Zounar R; Klener P
    Cas Lek Cesk; 1996 Jul; 135(14):450-3. PubMed ID: 8925545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?
    Wu WK; Duh MS; Lefebvre P
    Hepatology; 2007 Jul; 46(1):283; author reply 283-4. PubMed ID: 17596889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.